MS201408-0005C

MS201408-0005C is an investigational small molecule drug developed by Merck Serono. It is being studied in combination with other agents as a potential therapy for advanced or metastatic solid tumors. Publicly available data does not specify its precise molecular mechanism or targets, but the drug has been assessed in phase I clinical trials for oncology indications in combination regimens. There is currently no evidence it is approved or that it reached later-phase clinical development. It is distinct from M-4112, which is a dual IDO1 and TDO inhibitor developed by the same company for cancer applications, but MS201408-0005C is referenced as a separate compound in clinical trial documents[1][3][5][7].